Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties
作者： Sylvia Deppe , Rainer H Böger , Johanna Weiss , Ralf A Benndorf
DOI: 10.1517/17425255.2010.494597
关键词: Pharmacology 、 Medicine 、 Angiotensin II 、 Cardiovascular prevention 、 Pharmacodynamics 、 Angiotensin II receptor type 1 、 Angiotensin Receptor Blockers 、 Pharmacokinetics 、 Telmisartan
摘要: … Moreover, telmisartan was the first ARB to receive approval … for the reduction of cardiovascular morbidity in ACE inhibitor-… effect of telmisartan in cardiovascular risk reduction or whether …
informahealthcare.com参考文章(73)
Stephen C Benson, Rumiko Iguchi, Christopher I Ho, Koichi Yamamoto, Theodore W Kurtz, Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same? Journal of Hypertension. ,vol. 26, pp. 973- 980 ,(2008) , 10.1097/HJH.0B013E3282F56BA5
Masatomo Miura, Shigeru Satoh, Kazuyuki Inoue, Mitsuru Saito, Tomonori Habuchi, Toshio Suzuki, Telmisartan pharmacokinetics in Japanese renal transplant recipients. Clinica Chimica Acta. ,vol. 399, pp. 83- 87 ,(2009) , 10.1016/J.CCA.2008.09.020
John H. Laragh, Leslie Baer, Hans R. Brunner, Fritz R. Buhler, Jean E. Vaughan, Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease The American Journal of Medicine. ,vol. 52, pp. 633- 652 ,(1972) , 10.1016/0002-9343(72)90054-X
Michael Schupp, Jürgen Janke, Ronald Clasen, Thomas Unger, Ulrich Kintscher, Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferator–Activated Receptor-γ Activity Circulation. ,vol. 109, pp. 2054- 2057 ,(2004) , 10.1161/01.CIR.0000127955.36250.65
Joel M. Neutel, William H. Frishman, Susanne Oparil, Vasilios Papademitriou, Giles Guthrie, Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. American Journal of Therapeutics. ,vol. 6, pp. 161- 166 ,(1999) , 10.1097/00045391-199905000-00007
William Hollander, Role of hypertension in atherosclerosis and cardiovascular disease. American Journal of Cardiology. ,vol. 38, pp. 786- 800 ,(1976) , 10.1016/0002-9149(76)90357-X
S. D. Crowley, S. B. Gurley, M. J. Herrera, P. Ruiz, R. Griffiths, A. P. Kumar, H.-S. Kim, O. Smithies, T. H. Le, T. M. Coffman, Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 103, pp. 17985- 17990 ,(2006) , 10.1073/PNAS.0605545103
David H.G. Smith, Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril. Clinical Therapeutics. ,vol. 24, pp. 1484- 1501 ,(2002) , 10.1016/S0149-2918(02)80056-X
Anna J Battershill, Lesley J Scott, Telmisartan: a review of its use in the management of hypertension Drugs. ,vol. 66, pp. 51- 83 ,(2006) , 10.2165/00003495-200666010-00004
Ralf A Benndorf, Daniel Appel, Renke Maas, Edzard Schwedhelm, Ulrich O Wenzel, Rainer H Böger, Telmisartan Improves Endothelial Function in Patients With Essential Hypertension Journal of Cardiovascular Pharmacology. ,vol. 50, pp. 367- 371 ,(2007) , 10.1097/FJC.0B013E31811DFBE7